24 / 46
QoL con Radium 223 (ALSYMPCA)
• A significantly higher percentage of patients receiving radium-223 had a meaningful improvement in FACT-P total score
on treatment (24.6% vs 16.1%, respectively; P=0.020; OR=1.70 [95% CI 1.08-2.65])
• A significantly higher percentage of patients receiving radium-223 had improved utility scores on treatment versus
placebo (29.2% vs 18.5%, respectively; P=0.004; OR=1.82 [95% CI 1.21-2.74])
Nilsson S, et al.
Ann Oncol.
2016;27(5):868-74
40
10
0
20
30
Responders, %
Radium-223
Placebo
FACT-P total score
a
EQ-5D utility score
b
n=24
n=16
24.6%
16.1%
106/431
30/136
n=38
n=18
29.2%
18.5%
138/472
37/200
P
= 0.004
P
= 0.020
n/N